Results from prospective and retrospective trials evaluating cessation of TKIs in CML
IS indicates International Score; and Q-PCR, quantitative PCR.
*Previous stem cell transplantation was allowed in some patients.
†Assay sensitivity was not reported.
‡Second-generation TKIs, dasatinib and nilotinib after IM intolerance or suboptimal response to IM.
§This trial included 23 patients who had previously undergone an allogeneic stem cell transplant, 3 patients received second-generation TKIs for IM intolerance.
‖Some of these patients were included in the analysis of the Korean KIDS study as well.